奥马佐单抗
针灸科
医学
慢性荨麻疹
生活质量(医疗保健)
疾病
皮肤病科
重症监护医学
替代医学
内科学
免疫学
病理
免疫球蛋白E
抗体
护理部
作者
Pelin Hızlı,Burak Gülcen,Arzu Kılıç
出处
期刊:Medical Science Monitor
[International Scientific Information, Inc.]
日期:2024-10-15
卷期号:30
摘要
BACKGROUND:Chronic urticaria (CU) is a skin condition causing itchy hives that can significantly impact quality of life. While medications like omalizumab can help, some patients may seek additional relief. This study aimed to investigate the potential benefits of acupuncture, a traditional Chinese medicine practice, as an adjunctive therapy alongside omalizumab for CU patients. MATERIAL AND METHODS:We enrolled 31 CU patients who received acupuncture in addition to omalizumab (study group) and 30 CU patients who received omalizumab only (controls). Mean scores of each CU-Quality of life (QoL) and urticaria control test (UCT) scores after acupuncture were compared with the pre-acupuncture scores and with the scores of the controls. RESULTS:There was no significant difference in mean food limitation, symptom embarrassment, cosmetics, and sports scores before and after acupuncture (P>0.005). Other CU-QoL scores were significantly lower after acupuncture compared to pre-acupuncture scores (P<0.005). Mean total CU-QoL score was significantly lower (P<0.001) and mean UCT score was significantly higher (P=0.001) after acupuncture compared to pre-acupuncture scores. There was no significant difference in free time, falling asleep, waking up at night, tiredness, concentration, symptom embarrassment, public embarrassment, cosmetics, clothing limitation, and sports scores between the acupuncture and control groups (P>0.005). Other CU-QoL scores were significantly lower in the acupuncture group compared to the controls (P<0.005). Mean total CU-QoL score was significantly lower (P=0.006) and mean UCT score was significantly higher (P<0.001) in acupuncture group compared to the controls. CONCLUSIONS:Acupuncture is an effective adjunctive therapy for CU patients already receiving omalizumab, and can improve quality of life and disease control in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI